A Phase I, Open-label, Safety Study of Anti-inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Rilonacept (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms RID-A; RID1
Most Recent Events
- 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 09 Feb 2011 Planned end date changed from 1 Jun 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.